Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
MCL1 and BCL-xL levels in solid tumors are predictive of dinaciclib-induced apoptosis.
Booher RN, Hatch H, Dolinski BM, Nguyen T, Harmonay L, Al-Assaad AS, Ayers M, Nebozhyn M, Loboda A, Hirsch HA, Zhang T, Shi B, Merkel CE, Angagaw MH, Wang Y, Long BJ, Lennon XQ, Miselis N, Pucci V, Monahan JW, Lee J, Kondic AG, Im EK, Mauro D, Blanchard R, Gilliland G, Fawell SE, Zawel L, Schuller AG, Strack P. Booher RN, et al. Among authors: miselis n. PLoS One. 2014 Oct 7;9(10):e108371. doi: 10.1371/journal.pone.0108371. eCollection 2014. PLoS One. 2014. PMID: 25289887 Free PMC article.
Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors.
Moschos SJ, Sullivan RJ, Hwu WJ, Ramanathan RK, Adjei AA, Fong PC, Shapira-Frommer R, Tawbi HA, Rubino J, Rush TS 3rd, Zhang D, Miselis NR, Samatar AA, Chun P, Rubin EH, Schiller J, Long BJ, Dayananth P, Carr D, Kirschmeier P, Bishop WR, Deng Y, Cooper A, Shipps GW, Moreno BH, Robert L, Ribas A, Flaherty KT. Moschos SJ, et al. Among authors: miselis nr. JCI Insight. 2018 Feb 22;3(4):e92352. doi: 10.1172/jci.insight.92352. eCollection 2018 Feb 22. JCI Insight. 2018. PMID: 29467321 Free PMC article. Clinical Trial.
Final outcomes analysis of the cell product SQZ-PBMC-HPV Phase 1 trial in incurable HPV16+ solid tumors shows improved overall survival in patients with increased CD8+ T cell tumor infiltration.
Weaver AN, Iams WT, Park JC, Mita M, Holtick U, Gordon MS, Rodabaugh KJ, Dhani N, Neupane P, Taylor M, Amanda Duvall E, Jennings J, Miselis NR, Loughhead S, Warren MS, Bernstein H, Klussmann JP, Baranda J, Jimeno A. Weaver AN, et al. Among authors: miselis nr. Mol Carcinog. 2024 Aug;63(8):1421-1428. doi: 10.1002/mc.23738. Epub 2024 May 2. Mol Carcinog. 2024. PMID: 38695604 Clinical Trial.
Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors.
Jimeno A, Baranda J, Iams WT, Park JC, Mita M, Gordon MS, Taylor M, Dhani N, Leal AD, Neupane P, Eng C, Yeku O, Mita A, Moser JC, Butler M, Loughhead SM, Jennings J, Miselis NR, Ji RR, Nair N, Kornacker M, Zwirtes RF, Bernstein H, Sharei A. Jimeno A, et al. Among authors: miselis nr. Invest New Drugs. 2023 Apr;41(2):284-295. doi: 10.1007/s10637-023-01342-x. Epub 2023 Mar 3. Invest New Drugs. 2023. PMID: 36867316 Free PMC article. Clinical Trial.
11 results